

BUY

TARGET PRICE: 8.4€ \\

+232%

COMPANY UPDATE

IADADEMSTAT SHOWS NOTABLE ACTIVITY IN SCLC

ORYZON GENOMICS presented a clinical update from its Phase 2a CLEPSIDRA study at ESMO 2019. CLEPSIDRA is evaluating iadademstat in combination with chemotherapy (carboplatin-etoposide) as a second-line treatment for patients with ED-SCLC, who are platinum-sensitive and positive for prespecified biomarkers. In 8 evaluable patients, the combination achieved 4 partial responses and 2 long-lasting stable diseases. Considering very poor prognosis for 2L ED-SCLC, we are encouraged by the observed clinical activity. We reiterate our BUY rating and TP of €8.4.

Olga Smolentseva, PhD +33 1 44 88 88 09 osmolentseva@investsecurities.com

Thibaut Voglimacci -Stephanopoli +33 1 44 88 77 95 tvoglimacci@invest-securities.com

Encouraging clinical activity in hard-to-treat population

The company presented a clinical update from its Phase 2a CLEPSIDRA study of iadademstat at the annual meeting of European Society for Medical Oncology (ESMO 2019). Recall, iadademstat (ORY-1001), a LSD1 selective inhibitor, is being evaluated in two Phase 2a studies, ALICE and CLEPSIDRA. CLEPSIDRA is assessing safety and efficacy of idademstat in combination with standard of care chemotherapy (carboplatinetoposide) in patients with relapsed extensive-disease small cell lung cancer (ED-SCLC), who are positive for predictive biomarkers. According to CLEPSIDRA's trial design, the patients receive 4-6 cycles of the iadademstat plus carboplatin-etoposide therapy and thereafter treatment continues with iadademstat as monotherapy. The study includes 2 parts, and preliminary results from the Part 1 of CLEPSIDRA were presented at ESMO 2019.

The presented data showed that out of 8 evaluable patients, 4 achieved partial response (PR) and 2 long-lasting stable disease (SD) for more than 4 months (Exhibit 1). Notably, 1 patient with PR achieved substantial tumor reduction of 79% after 6 cycles of iadademstat plus chemotherapy. Moreover, tumor continued to shrink under monotherapy with iadademastat, reaching 86%, and the patient is still in remission after 6 cycles of iadademstat alone (currently at cycle 13 or nearly 10 months under treatment). The observed tumor response in this patient suggests that iadademstat could potentially achieve a long-lasting clinical effect. Another significant PR of 70% tumor reduction was achieved in patient, who died from unrelated medical cause. Among 2 other PRs: one developed into progressive disease (although patient did not receive the same amount of treatment due to hematoxicity) and another is currently ongoing (cycle 2 of therapy). Overall, considering that the backbone chemotherapy showed only 15-25% ORR in chemo-sensitive second-line SCLC patients, we believe that CLEPSIDRA's interim results suggest an encouraging clinical activity of iadademstat and supports further clinical development in this indication. CREPSIDRA is planning to recruit 36 patients, with expected topline results of the study in 2020.

ED-SCLC is a very aggressive type of cancer, with 2-year survival rate of ≤10%. Patients with SCLC have very poor prognosis and, while they respond well to initial chemotherapy, most of them develop recurrent disease. Moreover, while checkpoint inhibitors, such as anti-PD-1/L1 therapies, recently reshaped the landscape of treatment in non-small cell lung cancer (NSCLC), SCLC was shown to be less susceptible to these therapies

> key points Share price (€)

triciapies.			
in € / share	2019e	2020e	2021e
Adjusted EPS	-0.13	-0.29	-0.45
chg.	n.s.	n.s.	n.s.
estimates chg.	n.s.	n.s.	n.s.
au 31/12	2019e	2020e	2021e
PE	n.s.	n.s.	n.s.
EV/Sales	n.s.	n.s.	n.s.
EV/EBITDA	n.s.	n.s.	n.s.
EV/EBITA	n.s.	n.s.	n.s.
FCF yield*	n.s.	n.s.	n.s.
Div. yield (%)	n.s.	n.s.	n.s.

Number of Shares (m)		45.8	
Market cap. (€m)			116	
Free float (€m)		85		
ISIN		ES0167733015		
Ticker		ORY-ES		
DJ Sector		Health Technology		
	1m	3m	Ytd	
Absolute perf.	-1.9%	-23.4%	+16.9%	
Relative perf.	-1.8%	-20.7%	+2.6%	
Source : Fac	rtset Inve	st Securities	estimates	

* After tax op. FCF before WCR

Exhibit 1: Efficacy of iadademstat plus chemo in second-line ED-SCLC Patient ID# #2 #3 #5 #6 #7 #8 #9 20 RECIST 1.1 variation from screening) **Best Observed Response** NA yet 0 -20 -40 -60 -80 -100


Source: company's presentation, ESMO 2019

For instance, ROCHE's anti-PD-L1 therapy, Tecentriq, was recently approved as a first-line treatment in combination with chemotherapy for ED-SCLC, albeit improving an overall survival (OS) to only 12.3 months (vs 10.3 months for placebo). In the second-line setting, checkpoint inhibitors as monotherapy have shown 10-30% ORR and OS of up to 10 months.

Hematologic toxicities are attributed to chemotherapy

CLEPSIDRA's results also showed that while iadademstat plus chemotherapy treatment resulted in substantial hematologic toxicity (Grade 3 neutropenia 65%), it was mostly due to chemotherapy agents (Exhibit 2). We note that in previous studies, carboplatin plus etoposide also showed Grade 3-4 hematologic adverse events (neutropenia 16%, anemia 11%, thrombocytopenia 3%) as well as Grade 3-4 fatigue (20%) and Grade 3-4 anorexia (19%).

Exhibit 2: Safety profile of iadademstat on combination with chemo



Source: company's presentation, ESMO 2019



Considering that chemotherapy is widely used in the clinic, we believe that clinicians are accustomed to managing hematologic adverse events associated with chemotherapeutic agents. Additionally, in our view, the treatment regimen could be modified further to improve the safety profile of iadademstat plus carboplatinetoposide combination.

Reinforced sentiment for accelerated approval in SCLC

With high unmet medical need and recent failures of Rova-T from ABBVIE and Opdivo from BRISTOL-MAYERS SQUIBB in second-line SCLC, the FDA seems to be willing to ease the regulatory hurdles for novel therapies in this indication. As an example, the agency recently signaled a green light to PHARMAMAR to submit its chemotherapy, lurbinectedin, for accelerated approval in second-line SCLC. The Phase 2 basket study of lurbinectedin (Zepsyre) included 60 patients with second-line chemo-sensitive ED-SCLC. In this cohort, the drug achieved an overall response rate (ORR) of 45% and median duration of response of 6.2 months. In overall second-line SCLC population (n=105), lurbinectedin showed ORR of 35% and SD of 33%, with medium overall survival of 9.3 months. PHARMAMAR has also initiated the registration Phase 3 Atlantis study of lurbinectedin plus chemotherapeutic agent, doxorubicin, in comparison to other chemotherapy regimens (including topotecan and CAV) to move the drug through the regulatory approval. The readout of Atlantis study was expected in 2020, albeit in August 2019, the company announced that the FDA has accepted the accelerated approval filling based on the Phase 2 data. According to company, the results from Atlantis study would still be incorporated into the final lurbinectedin's regulatory filling, although there is no pressure to generate the outstanding data.

Thus, we believe that iadademstat could also aim for shortened clinical path and potentially accelerated approval in the future. We are currently expecting the full results of CLEPSIDRA study to reinforce this hypothesis. We currently project iadademstat to reach the market for second-line ED-SCLC in 2024 in the US and the EU, generating sales revenues of €81M and growing to €574M by 2031.



INVESTMENT CASE

ORYZON is a Spanish biotech specializing in the treatment of neurodegenerative diseases and cancer. In all its development programs, the company identifies biomarkers through its genetic and proteomic platforms in order to develop small molecule drugs. Looking ahead of multiple clinical updates, we believe that Oryzon's lead programs could significantly advance in 2019.

FINANCIAL DATA



Share information	2017	2018	2019e	2020e	2021e	2022e	2023e	2024e
Published EPS (€)	-0.15	-0.03	-0.13	-0.29	-0.45	0.52	0.43	0.75
Adjusted EPS (€)	-0.15	-0.03	-0.13	-0.29	-0.45	0.52	0.43	0.75
Diff. I.S. vs Consensus	-0.3%	-14.1%	-20.2%					
Dividend								
								-
Valuation ratios	2017	2018	2019e	2020e	2021e	2022e	2023e	2024e
P/E	n.s.	n.s.	n.s.	n.s.	n.s.	4.9x	5.9x	3.4x
EV/Sales	8265.92x	n.s.	n.s.	n.s.	n.s.	2.42x	4.13x	0.87x
VE/EBITDA	n.s.	n.s.	n.s.	n.s.	n.s.	3.8x	5.6x	2.2x
VE/EBITA	n.s.	n.s.	n.s.	n.s.	n.s.	3.8x	5.6x	2.2x
Op. FCF bef. WCR yield	n.s.	n.s.	n.s.	n.s.	n.s.	13.5%	11.4%	32.0%
Op. FCF yield	n.s.	n.s.	n.s.	n.s.	n.s.	13.5%	11.4%	32.0%
Div. yield (%)	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.
NB : valuation based on annu	al average pr	rice for past	exercise					
Entreprise Value (€m)	2017	2018	2019e	2020e	2021e	2022e	2023e	2024e
Share price in €	4.6	2.5	2.5	2.5	2.5	2.5	2.5	2.5
Market cap.	156	86	125	125	125	125	125	125
Net Debt	-17	-23	-30	-10	11	-5	-16	-42
	0			0	0	0	0	
Minorities Provisions/ poor-dobt		0	0					0
Provisions/ near-debt	0	0	0	0	0	0	0	0
+/- Adjustments Entreprise Value (EV)	0 139	0 64	96	0 116	0 136	0 121	0 109	0 83
Entreprise value (EV)	103	04	30	110	130	121	103	03
Income statement (€m)	2017	2018	2019e	2020e	2021e	2022e	2023e	2024e
Sales	0.0	0.0	0.0	0.0	0.0	50.0	26.5	96.3
chg.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.
EBITDA	-4	-3	-6	-12	-19	32	19	39
EBITA	-4	-3	-6	-12	-19	32	19	39
chg.	n.s.	n.s.	n.s.	n.s.	n.s.	n.s.	-39.2%	+98.9%
EBIT	-4.7	-3.3	-6.2	-12.2	-19.3	31.7	19.1	38.3
Financial result	-1	-1	-1	-1	-1	-1	-1	-1
Corp. tax	0	3	1	0	0	-9	0	-5
Minorities+affiliates	0	0	0	0	0	0	0	0
Net attributable profit	-5.2	-1.2	-5.7	-12.7	-19.8	22.5	18.6	32.8
Adjusted net att. profit	-5.2	-1.2	-5.7	-12.7	-19.8	22.5	18.6	32.8
				n.s.	n.s.	n.s.	-17.3%	+76.0%
chg.	n.s.	n.s.	n.s.					
						2022e	2023e	
Cash flow statement (€m)	2017	2018	2019e	2020e	2021e	2022e 32.0	2023e	2024e
Cash flow statement (€m) EBITDA	2017 -3.9	2018 -3.1	2019e -6.0	2020e -12.0	2021e -19.0	32.0	19.5	2024e 38.7
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA	2017 -3.9 0.1	2018 -3.1 2.5	2019e -6.0 1.0	2020e -12.0 0.0	2021e -19.0 0.0	32.0 -8.7	19.5 0.0	2024e 38.7 -5.1
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex	2017 -3.9 0.1 0.6	2018 -3.1 2.5 -7.0	2019e -6.0 1.0 -7.0	2020e -12.0 0.0 -7.0	2021e -19.0 0.0 -7.0	32.0 -8.7 -7.0	19.5 0.0 -7.0	2024e 38.7 -5.1 -7.0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR	2017 -3.9 0.1 0.6 -3.2	2018 -3.1 2.5 -7.0 -7.6	2019e -6.0 1.0 -7.0 -12.0	2020e -12.0 0.0 -7.0 -19.0	2021e -19.0 0.0 -7.0 -26.0	32.0 -8.7 -7.0 16.3	19.5 0.0 -7.0 12.5	2024e 38.7 -5.1 -7.0 26.7
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR	2017 -3.9 0.1 0.6 -3.2 -0.2	2018 -3.1 2.5 -7.0 -7.6 0.3	2019e -6.0 1.0 -7.0 -12.0 0.0	2020e -12.0 0.0 -7.0 -19.0 0.0	2021e -19.0 0.0 -7.0 -26.0 0.0	32.0 -8.7 -7.0 16.3 0.0	19.5 0.0 -7.0 12.5 0.0	2024e 38.7 -5.1 -7.0 26.7 0.0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0	32.0 -8.7 -7.0 16.3 0.0 16.3	19.5 0.0 -7.0 12.5 0.0	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0	32.0 -8.7 -7.0 16.3 0.0 16.3	19.5 0.0 -7.0 12.5 0.0 12.5 0.0	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 0.0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 0.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0 0.0	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m)	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 0.0 -19.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0 -20.0	32.0 -8.7 -7.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 0.0 -19.0 2020e 46	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0 -20.0 -20.0	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5 2023e 67	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 0.0 -19.0 2020e 46 44	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0 -20.0 2021e 53 51	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3 2022e 60 58	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5 2023e 67 65	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 -26.0 0.0 -20.0 -20.0 -20.0 -20.0	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5 2023e 67 65 -9	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9 47	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 -26.0 0.0 -20.0 2021e 53 51 -9 33	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5 2023e 67 65 -9 74	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9 47 0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0 -20.0 2021e 53 51 -9 33 0	32.0 -8.7 -7.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5 67 67 65 -9 74 0	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0 0	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0 0	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 -19.0 2020e 46 44 -9 47 0 0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0 -20.0 -20.0 2021e 53 51 -9 33 0 0	32.0 -8.7 -7.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 12.5 2023e 67 65 -9 74 0	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0 0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9 47 0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0 -20.0 2021e 53 51 -9 33 0	32.0 -8.7 -7.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5 67 67 65 -9 74 0	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0 0 -17.2	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0 0	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9 47 0 0 -10.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 6.0 0.0 -20.0 2021e 53 51 -9 33 0 10.8	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0 0 -4.7	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5 2023e 67 65 -9 74 0 0 -16.4	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0 0 -42.3
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0 0 -17.2	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0 -22.6	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0 -29.8	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9 47 0 0 -10.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 -26.0 0.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0 -20.0	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0 -4.7	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5 2023e 67 65 -9 74 0 0 -16.4	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0 0 -42.3
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0 0 -17.2	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0 0 -22.6	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0 0 -29.8 2019e n.s.	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 -19.0 2020e 44 -9 47 0 0 -10.0	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 -26.0 0.0 -20.0 2021e 53 51 -9 33 0 10.8	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0 0 -4.7	19.5 0.0 -7.0 12.5 0.0 12.5 0.0 0.0 0.0 0.0 12.5 2023e 67 65 -9 74 0 0 -16.4	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0 0 -42.3
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef, WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0 0 -17.2 2017 n.s. n.s.	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0 0 -22.6 2018 n.s. n.s.	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0 0 -29.8 2019e n.s. n.s.	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9 47 0 0 -10.0 2020e n.s. n.s.	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 -26.0 0.0 -20.0 2021e 53 51 -9 33 0 0 10.8 2021e n.s. n.s.	32.0 -8.7 -7.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0 0 -4.7	19.5 0.0 -7.0 12.5 0.0 0.0 12.5 0.0 0.0 0.0 12.5 67 65 -9 74 0 0 -16.4 2023e 73.5%	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0 0 -42.3 2024e 40.2% 40.2%
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin Adjusted Net Profit/Sales	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0 0 -17.2 2017 n.s. n.s.	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0 0 -22.6 2018 n.s. n.s.	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0 0 -29.8 2019e n.s. n.s.	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9 47 0 0 -10.0 2020e n.s. n.s.	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 -26.0 0.0 -20.0 2021e 53 51 -9 33 0 0 10.8 2021e n.s. n.s.	32.0 -8.7 -7.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0 0 -4.7 2022e 64.0% 64.0% 45.0%	19.5 0.0 -7.0 12.5 0.0 0.0 0.0 0.0 0.0 12.5 2023e 67 65 -9 74 0 0 -16.4 2023e 73.5% 73.5% 70.4%	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0 0 -42.3 2024e 40.2% 40.2% 34.0%
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin Adjusted Net Profit/Sales ROCE	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0 0 -17.2 2017 n.s. n.s.	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0 0 -22.6 2018 n.s. n.s. n.s.	2019e -6.0 1.0 -7.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0 0 -29.8 2019e n.s. n.s.	2020e -12.0 0.0 -7.0 -19.0 0.0 0.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9 47 0 0 -10.0 2020e n.s. n.s.	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 -26.0 0.0 -20.0 -20.0 -20.1 53 51 -9 33 0 0 10.8 -20.1	32.0 -8.7 -7.0 16.3 0.0 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0 0 -4.7	19.5 0.0 -7.0 12.5 0.0 0.0 0.0 0.0 0.0 12.5 2023e 67 65 -9 74 0 0 -16.4 2023e 73.5% 73.5% 70.4% 33.6%	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0 0 -42.3 2024e 40.2% 40.2% 34.0% 59.8%
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin Adjusted Net Profit/Sales	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0 0 -17.2 2017 n.s. n.s.	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0 0 -22.6 2018 n.s. n.s.	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0 0 -29.8 2019e n.s. n.s.	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 0.0 0.0 -19.0 2020e 46 44 -9 47 0 0 -10.0 2020e n.s. n.s.	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 -26.0 0.0 -20.0 2021e 53 51 -9 33 0 0 10.8 2021e n.s. n.s.	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0 0 -4.7 2022e 64.0% 64.0% 64.0% 62.8%	19.5 0.0 -7.0 12.5 0.0 0.0 0.0 0.0 0.0 12.5 2023e 67 65 -9 74 0 0 -16.4 2023e 73.5% 73.5% 70.4%	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0 0 -42.3 2024e 40.2% 40.2% 34.0%
Cash flow statement (€m) EBITDA Theoretical Tax / EBITA Capex Operating FCF bef. WCR Change in WCR Operating FCF Acquisitions/disposals Capital increase/decrease Dividends paid Other adjustments Published FreeCash Flow Balance Sheet (€m) Assets Intangible assets/GW WCR Group equity capital Minority shareholders Provisions Net financial debt Financial ratios EBITDA margin EBITA margin Adjusted Net Profit/Sales ROCE ROCE ROCE apper MCR Tenno MCR	2017 -3.9 0.1 0.6 -3.2 -0.2 -3.4 5.1 16.9 0.0 0.0 18.5 2017 25 22 -8 34 0 0 -17.2 2017 n.s. n.s. n.s.	2018 -3.1 2.5 -7.0 -7.6 0.3 -7.3 0.1 11.9 0.0 0.0 4.7 2018 32 29 -9 45 0 0 -22.6 2018 n.s. n.s. n.s.	2019e -6.0 1.0 -7.0 -12.0 0.0 -12.0 0.0 20.0 0.0 8.0 2019e 39 36 -9 59 0 0 -29.8 2019e n.s. n.s. n.s.	2020e -12.0 0.0 -7.0 -19.0 0.0 -19.0 0.0 -19.0 2020e 46 44 -9 47 0 0 -10.0 2020e n.s. n.s. n.s.	2021e -19.0 0.0 -7.0 -26.0 0.0 -26.0 0.0 -26.0 0.0 -20.0 2021e 53 51 -9 33 0 10.8 2021e n.s. n.s. n.s.	32.0 -8.7 -7.0 16.3 0.0 16.3 0.0 0.0 0.0 0.0 16.3 2022e 60 58 -9 55 0 0 -4.7 2022e 64.0% 64.0% 64.0% 45.0% 62.8% 40.5%	19.5 0.0 -7.0 12.5 0.0 0.0 0.0 0.0 0.0 12.5 2023e 67 65 -9 74 0 0 -16.4 2023e 73.5% 73.5% 70.4% 33.6% 25.1%	2024e 38.7 -5.1 -7.0 26.7 0.0 26.7 0.0 0.0 0.0 0.0 26.7 2024e 74 71 -9 107 0 -42.3 2024e 40.2% 40.2% 34.0% 59.8% 30.7%



SWOT ANALYSIS

STRENGTHS

OPPORTUNITIES

- Epigenetic platform
- Numerous clinical development programs

Expansion indications for clinical programs

Preclinical programs to move into clinic

Potential partnership agreement

Solid cash position


WEAKNESS

- No partnership
- Numerous failures in lead indication (AD)
- ☐ Tight competition in oncology indications

THREATS

- Clinical and regulatory risks
- Commercial risks
- Legal risks

SHARE PRICE CHANGE FOR 5 YEARS



DETECTION OF CONFLICTS OF INTEREST

	Corporate Finance	Treasury stocks holding	Prior communication to company	Analyst's personal interest	Liquidity contract	Listing Sponsor	Research Contract
Oryzon Genomics	No	No	Yes	No	No	No	Yes

DISCLAIMER

The present document does not constitute and is not part of any offer or solicitation for the purchase or sale of stocks and/or bonds issued by the issuers. While all the necessary precautions have been taken in order to assure that the facts mentioned in this present document are accurate and that the forecasts, opinions and scenarios contained in it are sincere and reasonable, Invest Securities has not verified the information contained in the present document and consequently neither Invest Securities nor any of its corporate officers, managers or employees may be held liable in any manner for its content. No guarantee is given regarding the accuracy, sincerity or completeness of the information contained in the present document. No persons accept any liability for any losses whatsoever resulting from the use of the present document or its contents or in any way linked to the present document. Research reports (including their preparation and distribution) are subject to the terms of Regulation (EU) no. 596/2014 of the European Parliament concerning market abuses. The present document is uniquely destined for (A) persons supplying third party portfolio management investment services and/or (B) qualified investors acting on their own behalf as defined in articles L.411-2, D.411-1 and D.411-4 of the Monetary and Financial Code. The present document has been supplied to you on a confidential basis and may not be reproduced or transmitted, in whole or part, to any other person or be published.

REPRODUCTION FORBIDDEN WITHOUT AUTHORIZATION.

MANAGEMENT

BIOTECH

Marc-Antoine Guillen

+33 1 44 88 77 80 maguillen@invest-securities.com

Jean-Emmanuel Vernay

Managing Director

+33 1 44 88 77 82 jevernay@invest-securities.com

Anne Bellavoine

Managing Director

+33 1 55 35 55 75 abellavoine@invest-securities.com

Pascal Hadjedj

Deputy Managing Director

+33 1 55 35 55 61 phadjedj@invest-securities.com

EQUITY RESEARCH

Maxime Dubreil

Head of Equity Research

+33 1 44 88 77 98 mdubreil@invest-securities.com

Johann Carrier

Stock-Picking

+33 1 44 88 77 88 jcarrier@invest-securities.com

Matthieu Lavillunière, CFA

Technology

+33 173 73 90 34 mlavilluniere@invest-securities.com

Jean-Louis Sempé

Automotive

+33 173 73 90 35 jlsempe@invest-securities.com

Bruno Duclos

Real Estate

+33 173 73 90 25 bduclos@invest-securities.com

Ludovic Martin, CFA

Consumer Goods

+33 173 73 90 36 Imartin@invest-securities.com

Olga Smolentseva

Biotechs

+33 1 44 88 88 09 osmolentseva@invest-securities.com

Benoit Faure-Jarrosson

Real Estate

+33 1 44 88 77 88 bfaure-jarrosson@invest-securities.com

Vladimir Minot

Real Estate

+33 173 73 90 25 vminot@invest-securities.com

Thibaut Voglimacci

Medtechs / Biotechs

+33 1 44 88 77 95 tvoglimacci@invest-securities.com

Christian Guyot

Consumer Goods

+33 1 80 97 22 01 cguyot@invest-securities.com

Thibault Morel

Technology

+33 1 44 88 77 97 tmorel@invest-securities.com

TRADING FLOOR

François Habrias

Institutional Sales

+33 1 55 35 55 70 fhabrias@invest-securities.com

Kaspar Stuart

Institutional Sales

+33 1 55 35 55 65 kstuart@invest-securities.com

Dominique Humbert

Sales trading

+33 1 55 35 55 64 dhumbert@invest-securities.com

Renaud Vallette Viallard

Institutional Sales

+33 172 38 26 32 rvv@invest-securities.com

Bertrand Le Mollé-Montanguon

Institutional Sales

+33 1 55 35 55 74 blmm@invest-securities.com

Frédéric Vals

Institutional Sales

+33 1 55 35 55 71 fvals@invest-securities.com

Ralph Olmos

Institutional Sales

+33 1 55 35 55 72 rolmos@invest-securities.com

CORPORATE BROKING & ISSUER MARKETING

Thierry Roussilhe

Head

+33 1 55 35 55 66 troussilhe@invest-securities.com

Claude Bouyer

Senior Advisor

+33 1 44 88 88 02 cbouyer@invest-securities.com